13F reference period
Q3 2026
Security Snapshot
Jazz Pharmaceuticals plc - COMMON STOCK (JAZZ) Institutional Ownership
CUSIP: G50871105
13F Institutional Holders and Ownership History from Q1 2014 to Q3 2026
Institutions Reporting
418
Shares (Excl. Options)
29.77M
Full value: 29,770,135 · shares · 30 Sep 2026Price
$231.52
The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / COMMON STOCK
- Symbol
- JAZZ on Nasdaq
- All holders as of 30 Sep 2026
- Q3 2026
- Total 13F shares
- 29,770,135
- Total 13F value
- $6,896,103,211
- Portfolio coverage rank
- 0.01%
- Share change
- +1,256,591
- Value change
- +$288,931,087
- Number of holders
- 418
- Shares outstanding
- 65,138,457
- SEC-reported price per share
- $210.39
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- JAZZ - Jazz Pharmaceuticals plc - COMMON STOCK is tracked under CUSIP G50871105.
- 418 institutions reported positions in Q3 2026.
- 2 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 648 to 418 between Q2 2026 and Q3 2026.
- SEC-reported value moved from to
$15.49B
Full value: $15,488,029,545 · USD · 30 Jun 2026.$6.9B
Full value: $6,896,103,211 · USD · 30 Sep 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 418 institutions filings for Q3 2026.
Security key
G50871105
13F reference period
Q3 2026
13F holders
418
13D/G owners
2
CIK / CUSIP context first
Open Q3 2026 holders
JAZZ full holder history
Jazz Pharmaceuticals plc SEC filings
Jazz Pharmaceuticals plc company facts
Jazz Pharmaceuticals plc insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP G50871105:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
2
Security
JAZZ
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 8.6% | +17% | $1,178,585,277 | +$194,915,395 | 5,601,907 | +20% | FMR LLC | 30 Sep 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | 5% | $633,056,418 | 3,103,522 | Vanguard Capital Management | 31 Mar 2026 |
As of 30 Sep 2026,
418
institutional investors reported holding
shares of
Jazz Pharmaceuticals plc - COMMON STOCK (JAZZ).
This represents
46%
of the company’s total
outstanding shares.
29.77M
Full value: 29,770,135 · shares · 30 Sep 202665.14M
Full value: 65,138,457 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
38%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4.7% | 3,071,767 | +1.2% | 0.03% | $711,175,496 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.3% | 2,805,176 | +2.8% | 0.01% | $649,454,348 |
| Capital World Investors | 3.7% | 2,393,393 | -11% | 0.07% | $554,119,801 |
| STATE STREET CORP | 3.2% | 2,067,988 | +3.4% | 0.01% | $478,780,582 |
| FRANKLIN TEMPLETON INC | 3% | 1,943,969 | -4.7% | 0.1% | $456,171,766 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.4% | 1,532,561 | +3.3% | 0.02% | $354,893,123 |
| DIMENSIONAL FUND ADVISORS LP | 2.2% | 1,453,265 | -15% | 0.06% | $336,463,332 |
| FULLER & THALER ASSET MANAGEMENT, INC. | 2.1% | 1,398,444 | -15% | 0.95% | $323,767,697 |
| Swedbank AB | 1.5% | 994,992 | +2.8% | 0.2% | $230,360,547 |
| Invesco Ltd. | 1.5% | 956,451 | +357% | 0.02% | $221,437,534 |
| MORGAN STANLEY | 1.1% | 704,600 | +12% | 0.01% | $163,129,317 |
| Mariner, LLC | 0.95% | 617,818 | +1.5% | 0.14% | $143,037,303 |
| AMERICAN CENTURY COMPANIES INC | 0.87% | 567,737 | +76% | 0.06% | $131,442,470 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | 0.82% | 535,457 | -0.66% | 0.1% | $123,969,005 |
| RENAISSANCE TECHNOLOGIES LLC | 0.74% | 483,573 | -14% | 0.15% | $111,956,821 |
| Quantinno Capital Management LP | 0.69% | 449,662 | +64% | 0.1% | $104,105,957 |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 0.66% | 428,249 | -2% | 0.32% | $99,148,208 |
| Boston Trust Walden Corp | 0.65% | 424,569 | -4.2% | 0.79% | $98,296,215 |
| VANGUARD FIDUCIARY TRUST CO | 0.63% | 408,208 | +3.5% | 0.02% | $94,508,316 |
| ASSETMARK, INC | 0.55% | 356,165 | +2864% | 0.14% | $82,459,205 |
| Polaris Capital Management, LLC | 0.49% | 320,466 | -2.6% | 7.8% | $74,194,288 |
| RAYMOND JAMES FINANCIAL INC | 0.39% | 257,025 | +12% | 0.02% | $59,506,587 |
| Qube Research & Technologies Ltd | 0.34% | 218,962 | -25% | 0.05% | $50,694,082 |
| FIRST TRUST ADVISORS LP | 0.33% | 212,777 | +182% | 0.03% | $49,262,131 |
| ARGENT CAPITAL MANAGEMENT LLC | 0.3% | 193,207 | -3.4% | 1.4% | $44,731,285 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
51
Headline period
Q3 2026
Rows shown
1-25 of 51
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 29,770,135 | $6,896,103,211 | +$288,931,087 | $231.52 | 418 |
| 2026 Q2 | 64,370,467 | $15,488,029,545 | -$37,107,670 | $240.97 | 648 |
| 2026 Q1 | 65,045,899 | $12,283,859,694 | +$702,069,385 | $189.05 | 575 |
| 2025 Q4 | 61,702,488 | $10,480,482,425 | +$192,018,597 | $170.00 | 573 |
| 2025 Q3 | 60,646,127 | $7,990,617,646 | -$150,715,669 | $131.80 | 498 |
| 2025 Q2 | 61,824,515 | $6,561,677,298 | +$172,218,482 | $106.12 | 497 |
| 2025 Q1 | 59,973,813 | $7,442,798,617 | +$115,230,167 | $124.15 | 545 |
| 2024 Q4 | 59,002,163 | $7,265,494,814 | +$147,830,867 | $123.15 | 502 |
| 2024 Q3 | 57,597,455 | $6,415,433,594 | +$58,344,093 | $111.41 | 469 |
| 2024 Q2 | 57,463,700 | $6,133,341,626 | -$38,433,148 | $106.73 | 451 |
| 2024 Q1 | 57,711,183 | $6,947,614,300 | +$89,820,559 | $120.42 | 475 |
| 2023 Q4 | 57,060,984 | $7,017,863,210 | -$56,981,989 | $123.00 | 491 |
| 2023 Q3 | 56,530,271 | $7,318,098,320 | -$17,277,114 | $129.44 | 482 |
| 2023 Q2 | 56,728,151 | $7,039,068,770 | -$22,114,573 | $123.97 | 465 |
| 2023 Q1 | 56,681,319 | $8,292,329,555 | +$108,158,178 | $146.33 | 462 |
| 2022 Q4 | 56,178,304 | $8,948,272,058 | -$100,056,709 | $159.31 | 475 |
| 2022 Q3 | 56,928,016 | $7,590,657,250 | -$96,379,512 | $133.29 | 443 |
| 2022 Q2 | 57,260,089 | $8,932,716,610 | +$138,065,500 | $156.01 | 448 |
| 2022 Q1 | 56,748,008 | $8,837,789,303 | -$111,358,494 | $155.67 | 437 |
| 2021 Q4 | 57,664,502 | $7,350,056,970 | +$21,422,030 | $127.40 | 422 |
| 2021 Q3 | 56,879,540 | $7,407,482,783 | -$119,725,201 | $130.21 | 422 |
| 2021 Q2 | 57,178,368 | $10,156,395,395 | +$780,868,772 | $177.64 | 481 |
| 2021 Q1 | 53,127,709 | $8,729,942,643 | +$29,540,811 | $164.37 | 435 |
| 2020 Q4 | 52,654,654 | $8,685,222,791 | -$294,935,573 | $165.05 | 428 |
| 2020 Q3 | 54,543,371 | $7,767,396,418 | +$369,110,226 | $142.59 | 382 |